Miao Shuo, Liu Houde, Yang Qingyu, Zhang Yaping, Chen Tao, Chen Shuai, Mao Xin, Zhang Qingsong
Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China; School of Basic Medicine, Qingdao University, Qingdao, China.
School of Basic Medicine, Qingdao University, Qingdao, China.
Pharmacol Res. 2024 Dec;210:107529. doi: 10.1016/j.phrs.2024.107529. Epub 2024 Nov 28.
Heart disease is a common human disease with high morbidity and mortality. Timely and effective prevention and treatment is an urgent clinical problem. The pathogenesis of heart disease is complex and diverse, involving hypertension, diabetes, atherosclerosis, drug toxicity, thrombosis, infection and other aspects. LL-37, an endogenous peptide, is well known for its antimicrobial properties. In recent years, LL-37 has been found to have a variety of biological functions, including its role in the regulation of atherosclerosis, thrombosis, inflammatory responses, and cardiac hypertrophy. Engineered LL-37-related peptides were developed and proved to regulate the development of disease, which revealed its potential clinical application. A comprehensive review and summary of LL-37 is presented to clarify its role in heart disease and to provide a reference and direction for future research.
心脏病是一种常见的人类疾病，发病率和死亡率都很高。及时有效的预防和治疗是一个紧迫的临床问题。心脏病的发病机制复杂多样，涉及高血压、糖尿病、动脉粥样硬化、药物毒性、血栓形成、感染等多个方面。LL-37是一种内源性肽，以其抗菌特性而闻名。近年来，LL-37被发现具有多种生物学功能，包括在动脉粥样硬化、血栓形成、炎症反应和心肌肥大调节中的作用。人们开发了工程化的LL-37相关肽，并证明其能调节疾病的发展，这揭示了其潜在的临床应用价值。本文对LL-37进行了全面的综述和总结，以阐明其在心脏病中的作用，并为未来的研究提供参考和方向。
